DE69719360D1 - Zusammensetzungen und methoden zur steigerung der darmfunktion - Google Patents

Zusammensetzungen und methoden zur steigerung der darmfunktion

Info

Publication number
DE69719360D1
DE69719360D1 DE69719360T DE69719360T DE69719360D1 DE 69719360 D1 DE69719360 D1 DE 69719360D1 DE 69719360 T DE69719360 T DE 69719360T DE 69719360 T DE69719360 T DE 69719360T DE 69719360 D1 DE69719360 D1 DE 69719360D1
Authority
DE
Germany
Prior art keywords
methods
increasing
glp
compositions
bowel function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69719360T
Other languages
English (en)
Other versions
DE69719360T2 (de
Inventor
J Drucker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
1149336 Ontario Inc
Original Assignee
1149336 Ontario Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 1149336 Ontario Inc filed Critical 1149336 Ontario Inc
Publication of DE69719360D1 publication Critical patent/DE69719360D1/de
Application granted granted Critical
Publication of DE69719360T2 publication Critical patent/DE69719360T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69719360T 1996-12-10 1997-12-10 Zusammensetzungen und methoden zur steigerung der darmfunktion Expired - Lifetime DE69719360T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/763,177 US5952301A (en) 1996-12-10 1996-12-10 Compositions and methods for enhancing intestinal function
PCT/CA1997/000945 WO1998025644A1 (en) 1996-12-10 1997-12-10 Compositions and methods for enhancing intestinal function

Publications (2)

Publication Number Publication Date
DE69719360D1 true DE69719360D1 (de) 2003-04-03
DE69719360T2 DE69719360T2 (de) 2003-12-04

Family

ID=25067085

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69719360T Expired - Lifetime DE69719360T2 (de) 1996-12-10 1997-12-10 Zusammensetzungen und methoden zur steigerung der darmfunktion

Country Status (10)

Country Link
US (1) US5952301A (de)
EP (1) EP0944396B1 (de)
AT (1) ATE233096T1 (de)
AU (1) AU5220098A (de)
CA (1) CA2274596C (de)
DE (1) DE69719360T2 (de)
DK (1) DK0944396T3 (de)
ES (1) ES2193406T3 (de)
PT (1) PT944396E (de)
WO (1) WO1998025644A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020025933A1 (en) * 1996-08-30 2002-02-28 Knudsen Liselotte Bjerre GLP-2 derivatives
CA2236519C (en) 1997-05-02 2011-09-13 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
BR9808804A (pt) * 1997-05-16 2001-09-18 Ontario Inc Processos para tratar um indivìduo para melhorar o funcionamento do trato gastrointestinal superior incluindo o esÈfago e o estÈmago, para tratar um indivìduo para proliferar o tecido do trato gastrointestinal superior, para identificar peptìdeos utilizável para tratar condições inflamatórias, para identificar peptìdeos, utilizável para evitar ou melhorar as condições inflamatórias, utilizável para identificar peptìdeos capazes de proliferar tecido do trato gastrointestinal superior, para tratar profilaticamente um indivìduo, para melhorar o crescimento do tecido do trato gastrointestinal superior em um mamìfero, e para tratar um indivìduo para melhorar o funcionamento do trato gastrointestinal superior, kit, processos para promover o crescimento de tecido do trato gastrointestinal superior ou células, para tratar um paciente para restaurar o trato gastrointestinal superior, para determinar a atividade de um hormÈnio quando usado em combinação com glp-2, para tratar um indivìduo tendo úlceras peptìdicas
EP1520582A3 (de) * 1998-02-02 2009-07-01 Trustees Of Tufts College Verwendung von Dipetidylpeptidasehemmer zur Regulierung des Glukosemetabolismus
AU7421598A (en) * 1998-05-11 1999-11-29 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
EP1104293A1 (de) * 1998-08-21 2001-06-06 Point Therapeutics, Inc. Regulierung von substrat aktivität
US6979697B1 (en) 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
GB9906715D0 (en) 1999-03-23 1999-05-19 Ferring Bv Compositions for promoting growth
GB9906714D0 (en) 1999-03-23 1999-05-19 Ferring Bv Compositions for improving fertility
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
CA2373643A1 (en) * 1999-05-25 2000-11-30 Point Therapeutics, Inc. Anti-tumor comprising boroproline compounds
EP1806138A1 (de) * 1999-05-25 2007-07-11 Point Therapeutics, Inc. Anti-tumor präparate enthaltend boroprolin verbindungen
WO2001032200A1 (en) * 1999-11-03 2001-05-10 Novo Nordisk A/S Use of a growth hormone or a growth hormone secretagogue for appetite-suppression or induction of satiety
US6599882B1 (en) 1999-11-05 2003-07-29 Joseph A. Rogoff Secretin and secretin pharmaceuticals for treating lactose intolerance
GB9930882D0 (en) * 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
PT1326630E (pt) 2000-09-18 2008-09-02 Sanos Bioscience As Utilização de péptidos glp-2
US7371721B2 (en) * 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US20080249016A1 (en) * 2000-09-18 2008-10-09 Sanos Bioscience A/S Use of GLP-2 in a combination treatment for bone-related disorders
US20070135345A1 (en) * 2000-09-18 2007-06-14 Henriksen Dennis B Use of GLP-2 for the treatment or prevention, of bone-related disorders
AU2002233089B2 (en) * 2001-02-16 2005-12-22 Conjuchem Biotechnologies Inc. Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders
JP2005511636A (ja) * 2001-11-26 2005-04-28 トラスティーズ オブ タフツ カレッジ 自己免疫疾患の治療方法及びそれに関する試薬
CA2468192A1 (en) 2001-11-26 2003-06-05 Trustees Of Tufts College Peptidomimetic inhibitors of post-proline cleaving enzymes
US20040038864A1 (en) * 2002-06-27 2004-02-26 Per Balschmidt Use of dimethyl sulfone as isotonicity agent
US7411039B2 (en) * 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
US20050026859A1 (en) * 2002-11-12 2005-02-03 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US20080026077A1 (en) * 2002-11-12 2008-01-31 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US7317109B2 (en) * 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7674913B2 (en) * 2003-11-12 2010-03-09 Phenomix Corporation Heterocyclic boronic acid compounds
US7576121B2 (en) * 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7767828B2 (en) * 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
CA2573209A1 (en) * 2004-07-14 2006-01-19 Novartis Ag Combination of dpp-iv inhibitors and compounds modulating 5-ht3 and/or 5-ht4 receptors
SI1877435T2 (sl) * 2005-05-04 2021-05-31 Zealand Pharma A/S Analogi glukagonu podobnega peptida-2(GLP-2)
US7825139B2 (en) * 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
EP2051995B1 (de) 2006-11-08 2017-02-08 Zealand Pharma A/S Selektive analoge des glucagon-ähnlichen peptids-2 (glp-2)
US20110295151A1 (en) * 2010-05-26 2011-12-01 Bakos Gregory J Enteroendocrine Manipulation for Metabolic Effect
KR20150006052A (ko) 2012-05-03 2015-01-15 질랜드 파마 에이/에스 글루카곤-유사 펩타이드-2 (ｇｌｐ-2) 유사체
EP4219534A3 (de) 2013-07-08 2023-09-27 The University of Utah Research Foundation Verfahren zur behandlung von und vorbeugung gegen entzündliche erkrankungen
WO2016184427A1 (zh) * 2015-05-21 2016-11-24 中国科学院上海生命科学研究院 低氧处理的间充质干细胞及其应用
CN106589110B (zh) * 2015-10-15 2020-01-17 上海迈迹生物医药科技有限公司 包含聚合物和glp-2衍生物的缀合物
WO2018104561A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
DK3881861T3 (da) 2017-06-16 2024-09-09 Zealand Pharma As Doseringsregimer for indgivelse af glukagonlignende peptid-2- (GLP-2)-analoger

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0607278B1 (de) * 1991-10-07 2002-04-17 The Brigham And Women's Hospital, Inc. Verfahren zur erhöhung der darmabsorption
NZ260309A (en) * 1992-06-08 1997-07-27 Pharmacia Ab Substituted For K Use of 1gf-2 for prevention or treatment of nutritional or gastrointestinal disorders and promoting neonatal growth
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
EP1231219B1 (de) * 1996-04-12 2010-08-25 1149336 Ontario Inc. Dem Glukagon ähnliches Peptid-2

Also Published As

Publication number Publication date
US5952301A (en) 1999-09-14
CA2274596C (en) 2004-11-09
ES2193406T3 (es) 2003-11-01
EP0944396A1 (de) 1999-09-29
ATE233096T1 (de) 2003-03-15
AU5220098A (en) 1998-07-03
PT944396E (pt) 2003-07-31
DE69719360T2 (de) 2003-12-04
DK0944396T3 (da) 2003-06-23
EP0944396B1 (de) 2003-02-26
WO1998025644A1 (en) 1998-06-18
CA2274596A1 (en) 1998-06-18

Similar Documents

Publication Publication Date Title
DE69719360D1 (de) Zusammensetzungen und methoden zur steigerung der darmfunktion
DK0981362T3 (da) Anvendelse af GLP-2-agonister, der forbedrer funktionen af den øvre mavetarmkanal
DE69736634D1 (de) Antagonisten des intestinotrophen glp-2 peptides
EP1231218A3 (de) Peptid zur Appetitzügelung, dessen Zusammensetzungen und Verwendung
EA200000445A1 (ru) Способы лечения состояния гиперкоагуляции или приобретенной недостаточности белка c
DE69731373D1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
ID26984A (id) Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
ATE218579T1 (de) Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin- analogen
DE69533991D1 (de) Dipeptide, die die ausschüttung von wachstumshormonen stimulieren
WO1998033509A3 (en) Useful properties of human lactoferrin and variants thereof
MXPA05002991A (es) Analogos de ghrh.
BR9607336A (pt) Composições de aminoácidos e utilidades das mesmas em nutrição clinica
ATE272628T1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
ES2168457T3 (es) Composiciones farmaceuticas que comprenden una superoxido dismutasa.
ATE232700T1 (de) Implantatkörper
BR0111506A (pt) Complexos de droga macromoleculares e composições contendo os mesmos
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
PE20050665A1 (es) ESTROGENOS SELECTIVOS DE 8ß-VINIL-ESTRA-1,3,5(10)-TRIEN-3,17ß-DIOL Y 17ß-FLUOR-9-VINIL-ESTRA-1,3,6(10)-TRIEN-3,16ALFA-DIOL
DE60024997D1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
ZA984838B (en) Bacterial pheromones and uses therefor.
DK1165102T3 (da) Matrixproteinpræparater til podning i ikke-mineraliseret væv
BR0109279A (pt) Antagonistas de lhrh, sua preparação e aplicação como medicamento
WO2004083241A3 (en) Btc-interacting proteins and use thereof
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine

Legal Events

Date Code Title Description
8364 No opposition during term of opposition